Literature DB >> 33611864

An immature inhibin-α-expressing subpopulation of ovarian clear cell carcinoma cells is related to an unfavorable prognosis.

Shinya Kusumoto1, Masako Kurashige1, Kenji Ohshima1, Shinichiro Tahara1, Takahiro Matsui1, Satoshi Nojima1, Satoshi Hattori2, Eiichi Morii1.   

Abstract

Inhibin-α, a member of transforming growth factor-β, is elevated in multiple tumors, but its specific roles are poorly understood. Here, we examined the feature of inhibin-α-expressing cells in ovarian tumors. Immunohistochemically, inhibin-α-expressing tumor cells were detected only in ovarian clear cell carcinoma (OCCC) among various types of ovarian tumors. By comparing the expression of inhibin-α and Ki-67, inhibin-α-expressing tumor cells were revealed to be less proliferative. When spheroids and chemoresistant cells were derived from OCCC cell lines, the expression level of inhibin-α was elevated, and that of an immature marker, aldehyde dehydrogenase, was also elevated. In consistent with this, inhibin-α expression was correlated with other immature markers, such as OCT3/4 and SOX2, and inversely correlated with proliferative marker MKI67 in public database on OCCC. Knockdown of inhibin-α in OCCC cell decreased chemoresistance. Moreover, prognostic analysis with 69 surgically resected OCCC cases revealed that the increased inhibin-α expression was an independent unfavorable prognostic factor. These findings suggested that inhibin-α-expressing subpopulation of OCCC tumor cells appeared to be less proliferative, immature, and angiogenic and to be related to acceleration of malignant progression.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33611864      PMCID: PMC7940216          DOI: 10.1002/cam4.3801

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  39 in total

1.  Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis.

Authors:  Yoo-Young Lee; Tae-Joong Kim; Min-Ji Kim; Ha-Jeong Kim; Taejong Song; Min Kyu Kim; Chel Hun Choi; Jeong-Won Lee; Duk-Soo Bae; Byoung-Gie Kim
Journal:  Gynecol Oncol       Date:  2011-06-02       Impact factor: 5.482

2.  Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.

Authors:  Ardian Latifi; Khalid Abubaker; Natalie Castrechini; Alister C Ward; Clifford Liongue; Francoise Dobill; Janani Kumar; Erik W Thompson; Michael A Quinn; Jock K Findlay; Nuzhat Ahmed
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

3.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

4.  What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Authors:  D S Chi; E L Eisenhauer; J Lang; J Huh; L Haddad; N R Abu-Rustum; Y Sonoda; D A Levine; M Hensley; R R Barakat
Journal:  Gynecol Oncol       Date:  2006-05-22       Impact factor: 5.482

5.  Adenocarcinomas of various sites may exhibit immunoreactivity with anti-inhibin antibodies.

Authors:  W G McCluggage; P Maxwell
Journal:  Histopathology       Date:  1999-09       Impact factor: 5.087

6.  Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.

Authors:  T Sugiyama; T Kamura; J Kigawa; N Terakawa; Y Kikuchi; T Kita; M Suzuki; I Sato; K Taguchi
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

7.  Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Michael J Sundborg; G Scott Rose; Peter G Rose; Stephen C Rubin; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-11-19       Impact factor: 44.544

8.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

9.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.

Authors:  Patrick C Hermann; Stephan L Huber; Tanja Herrler; Alexandra Aicher; Joachim W Ellwart; Markus Guba; Christiane J Bruns; Christopher Heeschen
Journal:  Cell Stem Cell       Date:  2007-09-13       Impact factor: 24.633

10.  The perivascular niche regulates breast tumour dormancy.

Authors:  Cyrus M Ghajar; Héctor Peinado; Hidetoshi Mori; Irina R Matei; Kimberley J Evason; Hélène Brazier; Dena Almeida; Antonius Koller; Katherine A Hajjar; Didier Y R Stainier; Emily I Chen; David Lyden; Mina J Bissell
Journal:  Nat Cell Biol       Date:  2013-06-02       Impact factor: 28.824

View more
  1 in total

1.  Low expression of INHB co-receptor TGFBR3 in connection with metastasis and immune infiltration in lung adenocarcinoma.

Authors:  Guoying Zou; Ying Wu; Biqiong Ren; Yuanyuan Wu; Qing Zhu; Junyu He; Zhihong Luo
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.